39
https://pubmed.ncbi.nlm.nih.gov/38117293
In individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse cardiovascular events and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications, but not when compared with SGLT2 inhibitors.